Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids

Inclusion Criteria: * Pediatric patients undergoing primary orthotopic liver transplantation (whole organ or split liver or reduced size) * Cadaveric or living donor (related or unrelated) Exclusion Criteria: * Patients who are recipients of multiple solid organ transplants and/or who have previously received transplanted organs * If cold ischemia time of the transplanted organ is \>12 hours * Auxiliary liver transplant recipients * Fulminant hepatic failure * Autoimmune hepatitis * Primary sclerosing cholangitis * Severe acute systemic infections * Hepatitis B surface antigen/HCV/HIV positive * Known contraindication to intravenous (i.v.) or per os (orally) (p.o.) cyclosporine or corticoids * Non-ability to comply with the protocol * Relevant abnormal physical or laboratory findings within 2 weeks of inclusion * Relevant severe allergy, hypersensitivity to basiliximab or similar drugs * History/presence of relevant malignancy * Pregnancy/breastfeeding * Use of any investigational or immunomodulatory/immunosuppressive drug within 4 weeks prior to transplantation.